Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry

Leukemia
M R BaerC D Bloomfield

Abstract

11q23 translocations (t(11q23)) are recurring cytogenetic abnormalities in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia, involving the same gene, ALL1 (or MLL). Mixed lineage antigen expression has been reported in these leukemias, but its frequency and clinical significance are unknown. We immunophenotyped leukemia cells from 19 adult de novo AML patients with t(11q23) by multiparameter flow cytometry. Translocations included t(6;11)(q27;q23), t(9;11)(p22;q23), t(9;11;19)(p22;q23;q13.3), t(2;11)(11;17)(q37;q11q23;q11), t(11;17)(q23;q25), t(11;19)(q23;p13.1), t(11;19)(q23;p13.3) and t(11;22)(q23;q11). FAB types were M4 and M5. The committed stem cell and myeloid antigens HLADr, CD4dim, CD11b, CD13, CD15, CD32, CD33, CD38 and CD64 were each expressed in 80-100% of cases, and the early stem cell and lymphoid antigens CD34, CD56, CD3, CD2 and CD7 in 42, 39, 16, 5 and 5%, respectively. Antigen expression frequencies did not differ from those in 443 adequately karyotyped M4 and M5 cases without t(11q23). Fifteen patients (79%) attained complete remission (CR); median CR duration and survival were 10.0 and 15.1 months. CR duration and survival did not correlate with antigen expression. In particular, patients wi...Continue Reading

Citations

Aug 7, 2002·Leukemia Research·Bin ZhangKe-Fu Wu
Nov 1, 2003·Best Practice & Research. Clinical Haematology·Tomasz SzczepańskiJacques J M van Dongen
Nov 1, 2003·Best Practice & Research. Clinical Haematology·Richard SchabathWolf Dieter Ludwig
Jul 3, 2013·Proceedings of the National Academy of Sciences of the United States of America·Hao HuangJianjun Chen
Mar 3, 2004·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Alberto OrfaoJesus San Miguel
Oct 7, 2009·American Journal of Hematology·Rebecca Pohlmann, Parul Bhargava
May 19, 2010·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Xin LiShi-Ang Huang
Mar 4, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hanneke M van der StraatenLeo F Verdonck
Jun 10, 2008·Cancer Cell·Junping WeiJames C Mulloy
May 18, 2001·Best Practice & Research. Clinical Haematology·K MrózekC D Bloomfield
Feb 19, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin S TallmanUNKNOWN Eastern Cooperative Oncology Group
May 29, 2002·Oncogene·Joseph M ScanduraStephen D Nimer
Jul 3, 2002·Leukemia·O Hrusák, A Porwit-MacDonald
Apr 12, 2003·Leukemia·M WetzlerM R Baer
Oct 19, 2001·Oncogene·M AlcalayP G Pelicci
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdClara D Bloomfield
May 28, 2010·Journal of Clinical and Experimental Hematopathology : JCEH·Ryuichi AmakawaShirou Fukuhara
Oct 1, 2021·Blood Cancer Journal·Ghayas C IssaFarhad Ravandi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.